118 related articles for article (PubMed ID: 11271495)
21. In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes.
Cervenková K; Belejová M; Chmela Z; Rypka M; Riegrová D; Michnová K; Michalíková K; Súrová I; Brejcha A; Hanus J; Cerný B; Fuksová K; Havlícek L; Veselý J
Physiol Res; 2003; 52(4):467-74. PubMed ID: 12899660
[TBL] [Abstract][Full Text] [Related]
22. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
23. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
24. In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route.
Chmela Z; Veselý J; Lemr K; Rypka M; Hanus J; Havlícek L; Krystof V; Michnová L; Fuksová K; Lukes J
Drug Metab Dispos; 2001 Mar; 29(3):326-34. PubMed ID: 11181503
[TBL] [Abstract][Full Text] [Related]
25. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
26. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
Hofman J; Ahmadimoghaddam D; Hahnova L; Pavek P; Ceckova M; Staud F
Pharmacol Res; 2012 Mar; 65(3):312-9. PubMed ID: 22173067
[TBL] [Abstract][Full Text] [Related]
27. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
[TBL] [Abstract][Full Text] [Related]
28. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs.
Hajdúch M; Havlíèek L; Veselý J; Novotný R; Mihál V; Strnad M
Adv Exp Med Biol; 1999; 457():341-53. PubMed ID: 10500810
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
30. Analysis on heat stress-induced hyperphosphorylation of stathmin at serine 37 in Jurkat cells by means of two-dimensional gel electrophoresis and tandem mass spectrometry.
Nakamura K; Zhang X; Kuramitsu Y; Fujimoto M; Yuan X; Akada J; Aoshima-Okuda M; Mitani N; Itoh Y; Katoh T; Morita Y; Nagasaka Y; Yamazaki Y; Kuriki T; Sobel A
J Chromatogr A; 2006 Feb; 1106(1-2):181-9. PubMed ID: 16427064
[TBL] [Abstract][Full Text] [Related]
31. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
Wesierska-Gadek J; Gueorguieva M; Kramer MP; Ranftler C; Sarg B; Lindner H
J Cell Biochem; 2007 Dec; 102(6):1405-19. PubMed ID: 17975794
[TBL] [Abstract][Full Text] [Related]
32. Cellular effects of olomoucine in human lymphoma cells differing in p53 function.
Fan S; Duba DE; O'Connor PM
Chemotherapy; 1999; 45(6):437-45. PubMed ID: 10567774
[TBL] [Abstract][Full Text] [Related]
33. Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia.
Sankrithi N; Eskin A
J Neurochem; 1999 Feb; 72(2):605-13. PubMed ID: 9930732
[TBL] [Abstract][Full Text] [Related]
34. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives as cyclin-dependent kinase inhibitors. Part II.
Oh CH; Kim HK; Lee SC; Oh C; Yang BS; Rhee HJ; Cho JH
Arch Pharm (Weinheim); 2001 Nov; 334(11):345-50. PubMed ID: 11822171
[TBL] [Abstract][Full Text] [Related]
36. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
37. Comparative proteomics analysis of the proteins associated with laryngeal carcinoma-related gene 1.
Zhang X; Xiao Z; Chen Z; Li C; Li J; Yanhui Y; Yang F; Yang Y; Oyang Y
Laryngoscope; 2006 Feb; 116(2):224-30. PubMed ID: 16467709
[TBL] [Abstract][Full Text] [Related]
38. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Krucher NA; Meijer L; Roberts MH
Cell Mol Neurobiol; 1997 Oct; 17(5):495-507. PubMed ID: 9353591
[TBL] [Abstract][Full Text] [Related]
39. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors.
Kim DC; Lee YR; Yang BS; Shin KJ; Kim DJ; Chung BY; Yoo KH
Eur J Med Chem; 2003 May; 38(5):525-32. PubMed ID: 12767603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]